

Phase I Trial: Quotient Code QSC303299

Submission date	Recruitment status	<input checked="" type="checkbox"/> Prospectively registered
23/01/2026	Not yet recruiting	<input type="checkbox"/> Protocol
Registration date	Overall study status	<input type="checkbox"/> Statistical analysis plan
06/02/2026	Deferred	<input type="checkbox"/> Results
Last Edited	Condition category	<input type="checkbox"/> Individual participant data
06/02/2026	Other	<input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr Philip Evans

Contact details

Mere Way, Ruddington Fields, Ruddington
Nottingham
United Kingdom
NG11 6JS
+44 (0)3303031000
recruitment@weneedyou.co.uk

Type(s)

Scientific, Public

Contact name

Dr Vicore Study Doctor

Contact details

Kornhamnstorg 53
Stockholm
Sweden
111 27
+46 (0)317880560
karin.eklund.vanderpol@vicorepharma.com

Additional identifiers

Integrated Research Application System (IRAS)
1013082

Study information

Scientific Title

Phase I Trial: Quotient Code QSC303299 [the full scientific title will be published within 30 months after the end of the trial]

Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

submitted 05/01/2026, London - Harrow REC (Health Research Authority, 2 Redman Place, Stratford, London, E201JQ, United Kingdom; +44 (0)2071048178; harrow.rec@hra.nhs.uk), ref: 26 /LO/0005

Primary study design

Interventional

Allocation

N/A: single arm study

Masking

Open (masking not used)

Control

Uncontrolled

Assignment

Single

Purpose

Phase I trial in healthy volunteers

Study type(s)

Health condition(s) or problem(s) studied

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

1. The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended. measured using - at -

Key secondary outcome(s)

Completion date

22/05/2026

Eligibility

Key inclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Healthy volunteers allowed

Yes

Age group

Mixed

Lower age limit

30 years

Upper age limit

65 years

Sex

Male

Total final enrolment

0

Key exclusion criteria

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

07/03/2026

Date of final enrolment

22/05/2026

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Quotient Sciences Limited

Mere Way

Ruddington Fields

Ruddington

Nottingham

England

NG11 6JS

Sponsor information

Organisation

Vicore Pharma (Sweden)

ROR

<https://ror.org/00mkdy143>

Funder(s)

Funder type

Funder Name

Vicore Pharma

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not expected to be made available